Ascentage Pharma Group International (ASPHF) News Today $10.65 0.00 (0.00%) As of 08/28/2025 Add Compare Share Share Headlines Stock AnalysisChartHeadlinesShort InterestBuy This Stock ASPHF Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Ascentage Pharma to Engage with Investors at September ConferencesAugust 28 at 4:51 PM | tipranks.comAscentage Pharma Reports Revenue Decline Amidst Strategic Drug ApprovalsAugust 20, 2025 | tipranks.comAscentage Pharma Group International (AAPG) Advances in Global Phase III Study for Higher-Risk ...August 17, 2025 | gurufocus.comAscentage Pharma Group International (AAPG) Advances in Global Phase III Study for Higher-Risk ...August 17, 2025 | gurufocus.comAscentage Pharma Schedules Board Meeting to Review Interim ResultsAugust 8, 2025 | tipranks.comAscentage Pharma Completes Share Placement and Subscription, Raising HK$1.49 BillionJuly 25, 2025 | tipranks.comAscentage Pharma’s Lisaftoclax Gains Approval for CLL/SLL Treatment in ChinaJuly 10, 2025 | tipranks.comAscentage Pharma Grants Further RSUs to Employees Under 2021 SchemeJune 27, 2025 | tipranks.comAscentage Pharma Reports Promising Study Results at EHA 2025June 15, 2025 | tipranks.comAscentage Pharma Group International (AAPG) Showcases Innovative Cancer Treatments at 2025 EHA ...June 9, 2025 | gurufocus.comAscentage Pharma Unveils Promising Clinical Data at ASCO 2025May 22, 2025 | tipranks.comAscentage Pharma Unveils Promising Preclinical Results at AACR 2025April 28, 2025 | tipranks.comAscentage Pharma Advances 2022 RSU Scheme with Share PurchaseApril 8, 2025 | tipranks.comAscentage Pharma Advances 2022 RSU Scheme with Share PurchaseMarch 31, 2025 | tipranks.comAscentage Pharma Group International GAAP EPS of -$0.18, revenue of $134.3MMarch 27, 2025 | seekingalpha.comAscentage Pharma Group International (AAPG) Showcases Innovative Cancer Therapies at AACR 2025March 25, 2025 | gurufocus.comAscentage Pharma to Showcase Innovative Cancer Therapies at AACR 2025March 25, 2025 | tipranks.comAscentage Pharma Raises $142.5 Million Through Partial Over-Allotment of ADSsFebruary 7, 2025 | tipranks.comAscentage Pharma Group International (AAPG) Announces Partial Exercise of Over-Allotment Option ...February 7, 2025 | gurufocus.comAscentage Pharma Successfully Closes ADS Offering, Raising Over US$112 MillionFebruary 2, 2025 | tipranks.comAscentage Pharma Group International (AAPG) Announces Successful U.S. IPOJanuary 28, 2025 | gurufocus.comTakeda-backed Ascentage Pharma aims to raise $126 mln in US IPOJanuary 23, 2025 | reuters.comAscentage Pharma Updates on Proposed U.S. IPO PlansJanuary 21, 2025 | tipranks.comTakeda-backed Ascentage Pharma targets $1.75 billion valuation in US IPOJanuary 21, 2025 | reuters.comAscentage Pharma Unveils Diverse Board LeadershipJanuary 1, 2025 | tipranks.comAscentage Pharma Appoints Esteemed Oncologist to BoardJanuary 1, 2025 | tipranks.comAscentage Pharma to Present at 43rd Annual J.P. Morgan Healthcare ConferenceDecember 26, 2024 | prnewswire.comLive from ASH 2024 | Oral Report Features Encouraging Data of Ascentage Pharma's Bcl-2 Inhibitor Lisaftoclax in R/R MM, Including a Median PFS Over 9 MonthsDecember 10, 2024 | prnewswire.comLive from ASH 2024 | Ascentage Pharma Releases Updated Data of Bcl-2 Inhibitor Lisaftoclax in MDS that Demonstrates Potential Clinical Benefits and Favorable SafetyDecember 10, 2024 | prnewswire.comLive from ASH 2024 | Ascentage Pharma's Bcl-2 Inhibitor Lisaftoclax in Combinations Demonstrates Potential Clinical Benefit in Patients with Prior Exposure to VenetoclaxDecember 10, 2024 | prnewswire.comAscentage Pharma Enhances Board with Strategic AppointmentsNovember 24, 2024 | tipranks.comAscentage Pharma’s Lisaftoclax Advances in Drug ApprovalNovember 17, 2024 | tipranks.comAscentage Pharma Announces a New Drug Application for Its Novel Bcl-2 Inhibitor Lisaftoclax Accepted and Recommended Priority Review Designation by CDE of China NMPANovember 17, 2024 | prnewswire.comASH 2024 | Results From Three Clinical Studies of Ascentage Pharma's Bcl-2 Inhibitor Lisaftoclax Selected for Presentations, Including an Oral ReportNovember 6, 2024 | prnewswire.comASH 2024 | Results From Three Clinical Studies of Ascentage Pharma's Bcl-2 Inhibitor Lisaftoclax Selected for Presentations, Including an Oral ReportNovember 6, 2024 | prnewswire.comLive from ESMO 2024 | Ascentage Pharma Releases Latest Data Showing Sustained Clinical Efficacy of Olverembatinib in SDH-Deficient GIST during a Mini Oral PresentationSeptember 13, 2024 | prnewswire.comESMO 2024 | Ascentage Pharma to Present Updated Data of Olverembatinib in Patients with SDH-Deficient GIST during a Mini Oral Presentation at the 2024 ESMO CongressSeptember 8, 2024 | prnewswire.comAscentage Pharma Announces 2024 Interim ResultsAugust 22, 2024 | prnewswire.comAscentage Pharma Received US$100 Million Option Payment from TakedaJuly 3, 2024 | prnewswire.comAscentage Pharma Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering of American Depositary SharesJune 23, 2024 | prnewswire.comLive from EHA 2024 | Ascentage Pharma Releases Updated Data of Lisaftoclax in Patients with R/R MM and AL Amyloidosis Highlighting Marked Improvement in ORRJune 17, 2024 | prnewswire.comAscentage Pharma Signs Option Agreement with Takeda to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)June 14, 2024 | prnewswire.comLive from ASCO 2024 | Ascentage Pharma Releases Updated Data Showing Promising Efficacy and Safety of Lisaftoclax in Patients with WMJune 4, 2024 | prnewswire.comLive from ASCO 2024 | Ascentage Pharma Releases Updated Data of FAK/ALK/ROS1 Inhibitor APG-2449 in Patients with NSCLCJune 1, 2024 | prnewswire.comASCO 2024 | Ascentage Pharma Releases Latest Results from Multiple Clinical Studies of Its Lead Drug CandidatesMay 23, 2024 | prnewswire.comEHA 2024 | Results from Five Studies of Ascentage Pharma's Key Drug Candidates Selected for Presentations at 2024 European Hematology Association Hybrid CongressMay 15, 2024 | prnewswire.comASCO 2024 | Ascentage Pharma to Present Four Studies, Including an Oral Report Featuring the Latest Data of Olverembatinib in SDH-Deficient GISTApril 24, 2024 | prnewswire.comAACR 2024 | Ascentage Pharma Presents Results from Three Studies at 2024 American Association of Cancer Research Annual MeetingApril 7, 2024 | prnewswire.com Get Ascentage Pharma Group International News Delivered to You Automatically Sign up to receive the latest news and ratings for ASPHF and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ASPHF Media Mentions By Week ASPHF Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ASPHF News Sentiment▼0.761.03▲Average Medical News Sentiment ASPHF News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ASPHF Articles This Week▼10▲ASPHF Articles Average Week Get the Latest News and Ratings for ASPHF and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Ascentage Pharma Group International and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies SXTPW News AGNPF News AKBLF News DRTSW News ASCLF News AVCTF News AWKNF News BRRGF News BCTXW News CRTHF News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:ASPHF) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ascentage Pharma Group International Please log in to your account or sign up in order to add this asset to your watchlist. Share Ascentage Pharma Group International With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access